Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients
Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, 1->3-β-D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL) and Blood Samples of Hematological High Risk Patients and to Detect Point Mutations Conferring Azole Resistance
Sponsor: Gilead Sciences
Listed as NCT01695512, this observational or N/A phase trial focuses on Acute Leukemia and Biomarkers and remains ongoing. Sponsored by Gilead Sciences, it has been updated 13 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
May 2022 — Jul 2024 [monthly]
Unknown Status
Status: Enrolling By Invitation → Unknown Status
-
Dec 2021 — May 2022 [monthly]
Enrolling By Invitation
-
Jan 2021 — Dec 2021 [monthly]
Enrolling By Invitation
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Enrolling By Invitation
-
May 2020 — Nov 2020 [monthly]
Enrolling By Invitation
-
Nov 2018 — May 2020 [monthly]
Enrolling By Invitation
-
Jun 2018 — Nov 2018 [monthly]
Enrolling By Invitation
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation
-
Apr 2018 — May 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Aug 2017 [monthly]
Enrolling By Invitation NA
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- Heidelberg University
For direct contact, visit the study record on ClinicalTrials.gov .